April, 2021 — Craif Inc. (formerly Icaria Inc.) (Headquarter: Bunkyo-ku, Tokyo, President & CEO: Ryuichi Onose, “Craif”) is pleased to announce that it has become a resident of Johnson & Johnson Innovation – JLABS @ Shanghai (‘JLABS’), which it considers as an important step toward further accelerating the development of an innovative exosome biomarker discovery platform, by getting access to JLABS’ global network and resources.

JLABS is a premier life science incubator program and a global network of open innovation ecosystems, which aims to enable and empower innovators to create and accelerate the delivery of potential life-enhancing health and wellness solutions to patients around the world.

Craif is a startup company founded in 2018. “NANO IP™ (NANO Intelligence Platform),” enables highly accurate detection of biological material such as microRNAs, related to diseases by using non-invasively collected bodily fluids, like urine. With this innovative platform, Craif is dedicated to developing screening tests using NANO IP™ to achieve early detection of cancer and provide the best medicine for everybody.

Craif’s core technology is a unique zinc oxide nanowire-based exosome extraction device.
Containing various biomolecules including proteins and nucleic acids, exosome is attracting worldwide attention for its potential as biomarkers for various diseases.
Craif’s device can not only efficiently extract exosomes, but also detect over 1,300 types of miRNA, which is deeply related to the development and progression of diseases. Combining AI with this leading-edge technology will hopefully enable us to succeed in detecting cancer with a high degree of accuracy.
As we continue to develop our technology, we aim to further increase the accuracy of our cancer detection method to facilitate early diagnosis and the selection of appropriate treatment for individual patients using urinary miRNA.
We will continue to strive to ultimately realize a future where no one will have to lose their battle with cancer.